AtaiBeckley (ATAI) Jefferies Global Healthcare Conference 2026 summary

Pipeline overview and differentiation

• Focused on mental health with three psychedelic assets: BPL-003 (intranasal 5-MeO-DMT), VLS-01 (oral DMT), and EMP-01 (oral MDMA), targeting depression and social anxiety disorder.

• BPL-003 and VLS-01 are positioned as second-generation products with modified pharmacokinetics for shorter, more manageable treatment sessions.

• Programs are designed to integrate into existing clinical infrastructure, leveraging models established by SPRAVATO and anticipated COMPASS approvals.

• EMP-01 showed positive phase IIa results in social anxiety disorder, with robust effects on regulatory and patient-reported outcomes.

Clinical trial progress and milestones

• BPL-003 phase III program initiated, with top-line results expected in early 2029; phase IIb showed strong efficacy and durability out to eight weeks.

• VLS-01 is in phase IIb, with top-line results anticipated in Q4 this year; next steps include a phase III trial if results are positive.

• EMP-01 phase IIa completed with positive results; further guidance on next steps will be provided soon.

• RECONNECT (phase III) trials for BPL-003 involve different dosing regimens and are sized to meet regulatory safety database requirements.

Regulatory and market environment

• Regulatory interactions have been positive and collaborative, with stability in leadership and enthusiasm for psychedelic therapies.

• Breakthrough Therapy designation achieved for BPL-003; recent executive orders may streamline DEA post-approval processes.

• The evolving regulatory stance has allowed for more flexible staffing and monitoring requirements in clinical settings.

• Market infrastructure is expected to support high-throughput, short-duration treatments, aligning with clinic economics.